Chemren Bio-Engineering Co., Ltd.

Omecamtiv mecarbil (CK-1827452) is a selective sarcomere-directed cardiac myosin activator with an EC50 of 0.6 μM.
IC50 value: 0.6 uM (EC50)
Target: myosin
Omecamtiv mecarbil, a novel cardiac muscle myosin activator, is currently the subject of a Phase II clinical trials program. This program was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of both intravenous and oral formulations of omecamtiv mecarbil for the potential treatment of heart failure across the continuum of care, in both hospital and outpatient settings. Omecamtiv mecarbil (CK-1827452; CK1827452 ) is useful for treatment of heart failure.